Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI112 in moderate to severe ulcerative colitis
NCT05377580Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of picankibart in ulcerative colitis (UC), sponsored by Innovent Biologics. Started Jul 2022; status: completed.
02
Drugs
picankibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05377580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377580.